Trial Profile

A Pilot Study of Safety and Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 25 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Feb 2022 Results assessing the the molecular response to brodalumab in hidradenitis suppurativa skin and serum, and to identify biomarkers of treatment response at week 12, published in the British Journal of Dermatology.
31 May 2021 Results assessing characterization of lesional relatively healthy-appearing perinodular (perilesional) and nonlesional hidradenitis suppurativa biopsies compared to site-matched healthy volunteer controls skin, published in the Journal of Allergy and Clinical Immunology.
03 Feb 2021 Results evalauting whether epithelialized tunnels are a source of inflammation in Hidradenitis Suppurativa, published in the Journal of Allergy and Clinical Immunology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com